Update publication information. Serological test is a powerful tool to help clinicians assess the patients’ status during COVID-19 treatment. Highly diverse serological outcomes as exemplified by the negative or overly high IgG and IgM expressions are frequently reported but never elucidated interpreted with molecular insights. We classed a patient cohort (N=144) into four groups based on their longitudinal serological patterns and compared their differences in clinical indicators across a two-year manifestation. Thereafter, four patients from each group (N=16) with 111 serum samples collected during the 10 weeks since disease onset were enrolled for proteomic analyses.